Perret C, Claeys M, Frey J G
Département de médecine, Centre hospitalier universitaire vaudois, Lausanne.
Schweiz Med Wochenschr. 1988 Apr 30;118(17):621-5.
The development of new inotropic or vasodilator agents, with different spectra of action makes possible a physiological approach to the treatment of acute cardiac failure. The choice depends on the functional disturbances measured and is then adapted to the response obtained. In the most serious cases, where pharmacological treatment proves insufficient, there need be no hesitation in using invasive methods which were formerly reserved for the treatment of cardiogenic shock. Systematic application of therapeutic formulae gives way to rational selection of the agent best adapted to the particular conditions brought about by a specified cardiopathy in a given patient.
新型具有不同作用谱的正性肌力药或血管扩张剂的研发，使采用生理学方法治疗急性心力衰竭成为可能。选择取决于所测量的功能障碍，然后根据所获得的反应进行调整。在最严重的病例中，若药物治疗被证明不足，毫不犹豫地使用以前仅用于治疗心源性休克的侵入性方法。治疗方案的系统应用让位于合理选择最适合特定患者特定心脏病所导致的特殊情况的药物。
